logo
Plus   Neg
Share
Email

Agios Pharmaceuticals Files For IPO Of Up To $86 Mln

Biopharmaceutical company Agios Pharmaceuticals Inc has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission to raise up to $86 million in an initial public offering of common stock. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Cambridge, Massachusetts-based company said in a preliminary prospectus that it intends to list its common stock on the Nasdaq under the symbol "AGIO".

The company, which was founded in 2007, specified that JP Morgan and Goldman Sachs & Co are lead underwriters in the IPO.

In April 2010, Agios entered into a collaboration agreement with Celgene corp (CELG.O) on a program focused on cancer metabolism.

Agios reported a net loss of $7.2 million on revenue of $6.3 million for the quarter ended March 31, according to the filing.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
While reporting financial results for the first quarter, American Express Co. (AXP) on Thursday affirmed its earnings and revenue growth guidance for the full-year 2019. For fiscal 2019, the company continues to project earnings in the range of $7.64 to $8.14 per share and adjusted earnings in the... While reporting financial results for the first quarter, Honeywell international Inc. (HON) on Thursday raised its earnings and sales outlook for the full-year 2019. For fiscal 2019, the company raised its earnings outlook to a range of $7.90 to $8.15 per share from the previous guidance range of... Chipmaker Intel Corp. said it plans to exit the 5G smartphone modem business, with the announcement coming just hours after Apple Inc. and Qualcomm Inc. said they have settled their royalty dispute. The settlement includes a payment from Apple to Qualcomm, but no details were disclosed about the payment or fees. Qualcomm's shares are gaining more than 14 percent in Wednesday's trading session.
Follow RTT